Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.
Packer M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, Pratt CM, Petrie MC, DeMets D, Kobrin I, Roux S, Swedberg K; ENABLE Investigators and Committees. Packer M, et al. Among authors: kobrin i. JACC Heart Fail. 2017 May;5(5):317-326. doi: 10.1016/j.jchf.2017.02.021. JACC Heart Fail. 2017. PMID: 28449795 Free article. Review.
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. Teerlink JR, et al. Among authors: kobrin i. Am Heart J. 2005 Jul;150(1):46-53. doi: 10.1016/j.ahj.2005.04.035. Am Heart J. 2005. PMID: 16084150
Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study.
Metra M, Cotter G, El-Khorazaty J, Davison BA, Milo O, Carubelli V, Bourge RC, Cleland JG, Jondeau G, Krum H, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Rainisio M, Kobrin I, McMurray JJ, Teerlink JR. Metra M, et al. Among authors: kobrin i. J Card Fail. 2015 Mar;21(3):179-88. doi: 10.1016/j.cardfail.2014.12.012. Epub 2015 Jan 5. J Card Fail. 2015. PMID: 25573829 Clinical Trial.
Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS.
Cotter G, Davison BA, Milo O, Bourge RC, Cleland JG, Jondeau G, Krum H, O'Connor CM, Metra M, Parker JD, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJ, Teerlink JR; VERITAS Investigators. Cotter G, et al. Among authors: kobrin i. J Card Fail. 2016 Oct;22(10):815-22. doi: 10.1016/j.cardfail.2015.12.017. Epub 2015 Dec 22. J Card Fail. 2016. PMID: 26721775 Free article. Clinical Trial.
Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?
Cotter G, Metra M, Davison BA, Jondeau G, Cleland JGF, Bourge RC, Milo O, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJV, Teerlink JR; VERITAS Investigators. Cotter G, et al. Among authors: kobrin i. Eur J Heart Fail. 2018 Feb;20(2):317-322. doi: 10.1002/ejhf.889. Epub 2017 Sep 4. Eur J Heart Fail. 2018. PMID: 28871621 Free article. Clinical Trial.
Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.
Cotter G, Kiowski W, Kaluski E, Kobrin I, Milovanov O, Marmor A, Jafari J, Reisin L, Krakover R, Vered Z, Caspi A. Cotter G, et al. Among authors: kobrin i. Eur J Heart Fail. 2001 Aug;3(4):457-61. doi: 10.1016/s1388-9842(01)00168-4. Eur J Heart Fail. 2001. PMID: 11511432 Free article. Clinical Trial.
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I. Torre-Amione G, et al. Among authors: kobrin i. J Am Coll Cardiol. 2003 Jul 2;42(1):140-7. doi: 10.1016/s0735-1097(03)00556-4. J Am Coll Cardiol. 2003. PMID: 12849674 Free article. Clinical Trial.
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. McMurray JJ, et al. Among authors: kobrin i. JAMA. 2007 Nov 7;298(17):2009-19. doi: 10.1001/jama.298.17.2009. JAMA. 2007. PMID: 17986694 Clinical Trial.
Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study.
Cotter G, Metra M, Davison BA, Senger S, Bourge RC, Cleland JG, Jondeau G, Krum H, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Milo O, Kobrin I, Rainisio M, McMurray JJ, Teerlink JR; VERITAS Investigators. Cotter G, et al. Among authors: kobrin i. Eur J Heart Fail. 2014 Dec;16(12):1362-71. doi: 10.1002/ejhf.186. Epub 2014 Nov 5. Eur J Heart Fail. 2014. PMID: 25371147 Free article. Clinical Trial.
100 results